Subthreshold laser treatment with Endpoint Management in posterior pole diseases associated with sub- and intraretinal fluid.

Not Applicable

Recruiting

Conditions: H35.7
Separation of retinal layers

Registration Number: DRKS00015437

Lead Sponsor: Augenklinik der Ludwig-Maximilians Universität München

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

Age =18 years, ability to give consent must be given, ability to participate in studies on a
regular basis must be given, BCVA better than 0,05, Diagnosis of optic disc pit maculopathy, exsudative choroidal naevus, MacTel type 2 or
persistent subretinal fluid after retinal detachment surgery (vitrectomy or buckling)
confirmed by retinal specialist, Normal findings in the medical history unless the investigator considers an abnormality to be
clinically irrelevant

Exclusion Criteria

Any other macular disease with possibility of developing subretinal fluid: vitreomacular traction syndrome, epiretinal membranes, age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, uveitis, Ocular surgery for 3 months preceding the study, Previous intravitreal injections of anti-VEGF, steroids within 3 months preceding the study, Previous macular laser treatment or photodynamic therapy within 6 months preceding the study, Present ocular infection or clinically significant inflammation, Kidney failure or dialysis, Women: Pregnancy or currently breast-feeding ,Allergy to fluorescein, History of systemic or topical corticosteroid use within last 6 months, Patient is not able to cooperate or has any other medical or psychological condition that prohibits him from regular follow-up, Planned intraocular surgery within 12 months

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of central subretinal fluid as measured by the decrease in central retinal thickness after 6 months (spectral-domain optical coherence tomography, SD-OCT) .

Secondary Outcome Measures

Name	Time	Method
Change in visual acuity (best corrected visual acuity measured by ETDRS<br>letters), Change in retinal sensitivity as measured by microperimetry, Change in Ellipsoid-Zone Defect<br>as measured by En-face-OCT after 12 months